<DOC>
	<DOCNO>NCT00381420</DOCNO>
	<brief_summary>The main objective study assess safety effectiveness sirolimus-coated Bx VELOCITY™ stent maintain minimum lumen diameter de novo native coronary artery lesion compare uncoated Bx VELOCITY™ balloon-expandable stent . Both stent mount Raptor® Stent Delivery Systems . The secondary objective ass cost-effectiveness express incremental cost/life year gain cost/quality adjust life year gain different time point ( 8 month , 1 year , 3 5 year ) .</brief_summary>
	<brief_title>The Study BX Velocity Stent Treatment De Novo Artery Lesions .</brief_title>
	<detailed_description>This multicenter , prospective , randomize double blind study . This study 2-arm design assess safety effectiveness sirolimus-coated Bx VELOCITY™ stent uncoated Bx VELOCITY™ stent , mount Raptor® Stent Delivery Systems . A total 100 patient enter study randomize 1:1 basis . Patients meet eligibility criterion either randomize Treatment A Treatment B . Neither investigator patient know stent implant . Patients follow 30 day , 6 , 9 , 12 month , 2 , 3 , 4 5 year post-procedure , patient undergo repeat angiography 8 month . Additionally , medical cost associate index hospitalization length stay , repeat hospitalization cost associate relevant medical resource use 5 year follow-up period collect analyzed .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , III ) OR patient document silent ischemia ; Single treatment de novo lesion major coronary artery patient single multivessel disease ; patient multiple lesion include lesion require treatment ; Target vessel diameter lesion site &gt; =2.50mm &lt; =3.0mm diameter ( visual estimate ) ; Target lesion &gt; =15mm &lt; =32mm length ( visual estimate ) ; Target lesion stenosis &gt; 50 % &lt; 100 % ( visual estimate ) ; Patient experience Qwave nonQwave myocardial infarction document total CK &gt; 2 time normal within precede 24 hour CK CKMB enzymes remain normal time treatment ; Has unstable angina classified Braunwald III B C A IIIIII , peri infarction ; Unprotected leave main coronary disease &gt; =50 % stenosis ; Significant ( &gt; 50 % ) stenoses proximal distal target lesion might require revascularization impede runoff ; Have ostial target lesion ; Angiographic evidence thrombus within target lesion ; Heavily calcify lesion successfully predilated ; Documented leave ventricular ejection fraction &lt; =25 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>